Wilms’ tumor 1 mRNA expression: a good tool for differentiating between myelodysplastic syndrome and aplastic anemia in children?

References

• Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154:185–195. doi: 10.1111/j.1365-2141.2011.08724.x
   PubMed Web of Science ®Google Scholar
• Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15:162–168. doi: 10.1097/MOH.0b013e3282fa7470
   PubMed Web of Science ®Google Scholar
• Elghetany MT. Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. Arch Pathol Lab Med. 2007;131:1110–1116.
   PubMed Web of Science ®Google Scholar
• Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). Leuk Res. 2010;34:1344–1350. doi: 10.1016/j.leukres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Mckenna RW. Myelodysplastic syndrome and myeloproliferative disorders in children. Am J Clin Pathol. 2004;122(Suppl 1):S58–S69.
   PubMedGoogle Scholar
• Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011;2011:84–89. doi: 10.1182/asheducation-2011.1.84
   PubMed Web of Science ®Google Scholar
• Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science. 1992;257:674–678. doi: 10.1126/science.1323141
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Sugisaki C, Nagata K, et al. Wilms’ tumor 1 message and protein expression in bone marrow failure and acute leukemia. Pathol Int. 2007;57:645–651. doi: 10.1111/j.1440-1827.2007.02153.x
   PubMed Web of Science ®Google Scholar
• Boublikova L, Kalinova M, Ryan J, et al. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression level, its impact on prognosis and minimal residual disease monitoring. Leukemia. 2006;20:254–263. doi: 10.1038/sj.leu.2404047
   PubMed Web of Science ®Google Scholar
• Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the international prognostic scoring system score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21:1988–1995. doi: 10.1200/JCO.2003.10.503
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Matsuda Y, Takai M, et al. Wilms’ tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia. Anticancer Res. 2012;32:4479–4483.
   PubMed Web of Science ®Google Scholar
• Shimada A, Taki T, Koga D, et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;96:469–476. doi: 10.1007/s12185-012-1163-1
   PubMed Web of Science ®Google Scholar
• Ho PA, Alonzo TA, Gerbing RB, et al. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61:81–88. doi: 10.1002/pbc.24700
   PubMed Web of Science ®Google Scholar
• Ueda Y, Mizutani C, Nannya Y, et al. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma. 2013;54:1450–1458. doi: 10.3109/10428194.2012.745074
   PubMed Web of Science ®Google Scholar
• Qin YZ, Zhu HH, Liu YR, et al. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. Leuk Lymphoma. 2013;54:1442–1449. doi: 10.3109/10428194.2012.743656
   PubMed Web of Science ®Google Scholar
• Woehlecke C, Wittig S, Arndt C, et al. Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases. J Cancer Res Clin Oncol. 2015;141:523–529. doi: 10.1007/s00432-014-1832-y
   PubMed Web of Science ®Google Scholar
• Tamura H, Dan K, Yokose N, et al. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leukemia Res. 2010;34:986–990. doi: 10.1016/j.leukres.2009.11.029
   PubMed Web of Science ®Google Scholar
• Baumanm I, Niemeyer CM, Bennett JM, et al. International agency for research on cancer. WHO classification of tumors of haematopoietic and lymphoid tissue. Geneva, Switzerland: World Health Organization; 2008; p. 104–107.
   Google Scholar
• Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63–70.
   PubMed Web of Science ®Google Scholar
• Qin YZ, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leukemia Res. 2009;33:384–390. doi: 10.1016/j.leukres.2008.08.026
   PubMed Web of Science ®Google Scholar
• Baba M, Hata T, Tsushima H, et al. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons. Intern Med. 2015;54:445–451. doi: 10.2169/internalmedicine.54.3123
   PubMed Web of Science ®Google Scholar
• Cheng YF, Zhang LP, Liu YR, et al. Clinical significance of the Wilms’ tumor 1 mRNA expression in childhood myelodysplastic syndrome. Zhonghua Xue Ye Xue Za Zhi. 2012;33:536–540. [in Chinese].
   PubMedGoogle Scholar
• Bader P, Niemeyer C, Weber G, et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol. 2004;73:25–28. doi: 10.1111/j.1600-0609.2004.00260.x
   PubMed Web of Science ®Google Scholar
• Nagasaki J, Aoyama Y, Hino M, et al. Wilms tumor 1 (WT1) mRNA expression level at diagnosis is a significant prognostic marker in elderly patients with myelodysplastic syndrome. Acta Haematol. 2017;137(1):32–39. doi: 10.1159/000452732
   PubMed Web of Science ®Google Scholar
• Glaubach T, Robinson LJ, Corey SJ. Pediatric myelodysplastic syndromes: they do exist!. J Pediatr Hematol Oncol. 2014;36:1–7. doi: 10.1097/MPH.0000000000000046
   PubMed Web of Science ®Google Scholar